drugset / Trial / NCT05644626
Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BGB-B167 monotherapy and in combination with tislelizumab (BGB-A317) in participants with select advanced solid tumors in Chinese participants
Timeline
- Start
- 2024-03
- Primary completion
- 2025-03
- Completion
- 2025-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BGB-B167 | Unknown | — | Intravenous |
| Subject | Tislelizumab | Monoclonal antibody | — | Intravenous |